These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22869166)

  • 1. The fat of the matter.
    Nat Med; 2012 Aug; 18(8):1155. PubMed ID: 22869166
    [No Abstract]   [Full Text] [Related]  

  • 2. Companies throw their weight behind new antiobesity drugs.
    Cahoon L
    Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-obesity drugs: to be or not to be?
    Dvorak RV; Sharma AM; Astrup A
    Obes Rev; 2010 Dec; 11(12):833-4. PubMed ID: 21054758
    [No Abstract]   [Full Text] [Related]  

  • 4. Fat pill for teens. Xenical may have the FDA's blessing, but is it a good idea?
    Gupta S
    Time; 2003 Dec 29-2004 Jan 5; 162(26):162. PubMed ID: 14722944
    [No Abstract]   [Full Text] [Related]  

  • 5. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 6. Slim spoils for obesity drugs.
    Ledford H
    Nature; 2010 Dec; 468(7326):878. PubMed ID: 21164452
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA approves first canine diet drug.
    Nolen RS
    J Am Vet Med Assoc; 2007 Mar; 230(5):641-2. PubMed ID: 17380625
    [No Abstract]   [Full Text] [Related]  

  • 8. Two new drugs approved for obesity.
    Johnson AM
    S D Med; 2012 Sep; 65(9):356-7. PubMed ID: 23066610
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?
    Downey M; Still C; Sharma AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Oct; 18(5):321-7. PubMed ID: 21878755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug management of obesity--efficacy versus safety.
    Astrup A
    N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
    [No Abstract]   [Full Text] [Related]  

  • 11. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
    Bays HE
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonincretin drugs in later-stage development.
    Zimmerman MP; Mehr SR
    Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226
    [No Abstract]   [Full Text] [Related]  

  • 14. An audience with Abraham Thomas. Interview by Asher Mullard.
    Thomas A
    Nat Rev Drug Discov; 2011 Feb; 10(2):90-1. PubMed ID: 21283097
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.
    Aggarwal R; Vaduganathan M; Chiu N; Bhatt DL
    Prog Cardiovasc Dis; 2021; 68():97-98. PubMed ID: 34560122
    [No Abstract]   [Full Text] [Related]  

  • 16. Beyond ephedra. Why the FDA's ban may lead users to look for other weight-loss stimulants.
    Gupta S
    Time; 2004 Jan; 163(2):78. PubMed ID: 14735657
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant FDA approvals in 1999.
    McGinnis TJ
    Am Fam Physician; 2000 Apr; 61(8):2531-3. PubMed ID: 10794586
    [No Abstract]   [Full Text] [Related]  

  • 19. Obesity in Europe - does anybody care?
    Astrup A; Rössner S; Finer N; Van Gaal L
    Expert Opin Pharmacother; 2013 Jun; 14(8):971-3. PubMed ID: 23517073
    [No Abstract]   [Full Text] [Related]  

  • 20. The pharmacologic management of obesity.
    Cerda JJ
    J Fla Med Assoc; 1997 Feb; 84(2):89-92. PubMed ID: 9066231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.